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Abstract
Objective:  Data  on  clinical  practice  in  pediatrics  on  the  use  of  analgesic,  antipyretic,  and
nonsteroidal  anti-inﬂammatory  drugs  considering  the  best  available  evidence  and  regulatory-
agency approved  use  are  uncertain.  This  study  aimed  to  determine  the  frequency  of  prescription
of these  drugs  according  to  the  best  scientiﬁc  evidence  and  use  approved  by  regulatory  agencies.
Methods: This  was  a  cross-sectional  study  of  150  pediatric  prescriptions  containing  analgesic,
antipyretic,  and  nonsteroidal  anti-inﬂammatory  drugs,  followed  by  interview  with  caregivers  at
18 locations  (nine  private  drugstores  and  nine  Basic  Health  Units  of  the  Brazilian  Uniﬁed  Health
System).  The  assessed  outcomes  included  recommended  use  or  use  with  no  contraindication,
indications  with  beneﬁt  evidence,  and  health  surveillance  agency-approved  use.  Data  were
analyzed in  electronic  databases  and  the  variables  were  summarized  by  simple  frequency.
Results: A  total  of  164  analgesic,  antipyretic,  and  nonsteroidal  anti-inﬂammatory  drugs  were
prescribed  to  150  children  aged  1--4  years  (38.6%).  Dipyrone  was  included  in  82  (54.6%)  and
ibuprofen  in  40  (26.6%)  prescriptions.  Non-recommended  uses  were  identiﬁed  in  15%  of  pre-
scriptions and  contraindicated  uses  were  observed  in  13.3%.  Nimesulide  (1.5%)  is  still  prescribed
to children  younger  than  12  years.  The  dose  was  incorrect  in  74.3%  of  prescriptions  contain-
ing dipyrone.  Of  the  211  reported  clinical  indications,  56  (26.5%)  had  no  evidence  of  beneﬁt
according  to  the  best  available  scientiﬁc  evidence  and  66  (31.3%)  had  indications  not  approved
by the  regulatory  agencies.
Conclusion:  There  are  signiﬁcant  discrepancies  between  clinical  practice  and  recommended
use of  analgesic,  antipyretic,  and  nonsteroidal  anti-inﬂammatory  drugs  in  pediatrics.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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em  prescric¸ão  pediátrica
Resumo
Objetivo:  Dados  sobre  a  prática  clínica  em  pediatria  no  uso  de  analgésicos,  antipiréticos  e
anti-inﬂamatórios  não  esteroides  considerando  a  melhor  evidência  disponível  e  uso  aprovado
por agências  reguladoras  são  incertos.  Este  estudo  tem  como  objetivo  veriﬁcar  a  frequência  de
prescric¸ão de  tais  medicamentos  segundo  a  melhor  evidência  cientíﬁca  e  o  uso  aprovado  por
agências reguladoras.
Método:  Estudo  transversal  de  150  prescric¸ões  pediátricas,  contendo  analgésicos,  antipiréticos
e anti-inﬂamatórios  não  esteroides,  seguido  de  entrevista  aos  cuidadores,  em  dezoito  locais
(nove drogarias  privadas  e  nove  Unidades  de  Saúde  do  SUS).  Os  desfechos  avaliados  incluíram
uso recomendado  ou  sem  contraindicac¸ão,  indicac¸ões  com  evidência  de  benefício  e  o  uso  autor-
izado por  agências  de  vigilância  sanitária.  Os  dados  foram  analisados  em  banco  eletrônico  e  as
variáveis sumarizadas  por  frequência  simples.
Resultados:  Foram  prescritos  164  analgésicos,  antipiréticos  e  anti-inﬂamatórios  não  esteroides
para as  150  crianc¸as  com  idade  entre  1  e  4  anos  (38,6%).  Dipirona  constou  em  82  (54,6%)
e ibuprofeno  em  40  (26,6%).  Usos  não  recomendados  foram  encontrados  em  15%  das  receitas  e
usos contraindicados  em  13,3%.  Nimesulida  (1,5%)  ainda  é  utilizada  em  crianc¸as  com  menos
de 12  anos.  Em  74,3%  das  prescric¸ões  contendo  dipirona  a  dose  estava  incorreta.  Das
211 indicac¸ões  clínicas  referidas  56  (26,5%)  não  tinham  evidências  de  benefício  segundo  a
melhor prova  cientíﬁca  disponível,  66  (31,3%)  eram  indicac¸ões  não  aprovadas  em  agências  de
vigilância  sanitária.
Conclusão:  Existem  importantes  discrepâncias  entre  prática  clínica  e  recomendac¸ões  de  uso  de
analgésicos,  antipiréticos  e  anti-inﬂamatórios  não  esteroides  em  pediatria.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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n  Brazil,  as  in  other  developing  countries,  regulatory
olicies  and  regulations  on  the  sales  and  prescription  of
edications  for  the  pediatric  age  range  are  still  insufﬁcient
or  the  sector  to  be  free  of  risks  related  to  inadequate  drug
rescriptions  and  uses.
Analgesics,  antipyretics  and  nonsteroidal  anti-
nﬂammatory  drugs  (NSAIDs)  are  the  most  often  prescribed
edications  in  the  pediatric  age  group.1 Predominantly
aproxen,  ketoprofen,  and  ibuprofen,  which  are  over-the-
ounter  (OTC)  medications  regulated  by  RDC  No.  138/2003.2
imesulide  and  other  drugs  of  the  same  group,  although  not
ncluded  in  the  OTC  list,  can  be  purchased  in  any  pharmacy
n  Brazil  without  a  prescription.
Although  these  drugs  have  potential  adverse  effects,
hey  are  widely  sold  in  pharmacies,  disregarding  restric-
ions  of  use,  indications,  toxicity,  and  contraindicated  drug
nteractions.  They  are  often  prescribed  without  a  deﬁned
herapeutic  goal,  generating  unnecessary  costs.
For  mild  to  moderate  pain,  in  general,  analgesics  with-
ut  anti-inﬂammatory  effect  (low-dose  acetylsalicylic  acid
nd  ibuprofen,  or  paracetamol)  should  be  prescribed.  NSAIDs
ave  similar  efﬁcacy,  but  their  selection  should  consider
elative  toxicity,  cost,  and  approved  age  group  (based  on
afety  and  efﬁcacy  studies  for  the  drug).  NSAIDs  have  an
‘all  or  nothing’’  effect,  i.e.,  increasing  the  dose  does
ot  increase  therapeutic  efﬁcacy,  but  results  in  increased
dverse  effects.3
l
a
IAlthough  fever  is  a  beneﬁcial  response  in  most  cases,  it
s  an  important  cause  of  anxiety  for  parents  and  physicians.
he  search  for  more  efﬁcient  treatments  has  led  to  the  use
f  antipyretic  combinations  in  pediatrics,  much  appreciated
y  caregivers  and  healthcare  professionals,  but  whose  efﬁ-
acy  has  been  tested  for  only  a  few  years  in  clinical  trials.4--6
he  new  schemes  consist  of  combinations  of  ibuprofen  and
aracetamol  administered  at  varying  times.  The  main  con-
ern  with  these  treatments  is  safety,  as  they  may  increase
he  risk  of  kidney  toxicity  and  Streptococcus  infection.7,8
herefore,  it  is  not  known  whether  these  combinations  are
ore  effective  than  and  as  safe  as  monotherapy  in  children
ith  fever.6
In  developed  countries,  the  indication  of  analgesics,
ntipyretics,  and  NSAIDs  in  pediatric  patients  is  extremely
imited.  Currently,  only  two  drugs  are  approved  by  the  Euro-
ean  Medicine  Agency  (EMEA)  for  the  treatment  of  fever  in
hildren:  paracetamol  and  ibuprofen.9 Millions  of  euros  have
een  spent  to  raise  awareness  among  prescribers  regarding
he  rational  use  of  drugs,  seeking  to  modify  inadequate  pre-
cription  criteria  and  habits.10
Drug  prescription  is  a  legal  document,  for  which  the
erson  prescribing  the  drug  (physician)  and  the  person
ispensing  it  (pharmacist)  are  responsible  and  subject  to
anitary  control  and  surveillance  legislation.Children  are  considered  ‘‘therapeutic  orphans,’’  due  to
ack  of  clinical  studies  with  this  population.  The  treatments
re  based  on  extrapolations  of  doses  developed  for  adults.
n  practice,  the  drug  is  often  used  at  indications,  doses,  and
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monly  observed  drug  was  dipyrone  in  82  cases  (54.7%),
followed  by  ibuprofen,  in  40  (26.7%;  Table  1).  Accord-
ing  to  the  International  Classiﬁcation  of  Diseases  (ICD  10)
the  most  frequent  clinical  indications  for  dipyrone,  in  68
Table  1  Reported  clinical  indications.
Drug  (ATC
classiﬁcation)
n  =  150  (%)  n  =  211  (%)
Prescriptions  Indications
Acetylsalicylic  acid
(N02BA01,  B01A)
5  (3.3)  5  (2.3)
Ketoprofen
(M01AE03)
16 (10.7)  19  (9.0)
Dipyrone  (N02BB02)  82  (54.7)  107  (50.7)
Ibuprofen  (M01AE01)  40  (26.7)  52  (24.6)
Nimesulide  (M01AX17)  2  (1.3)  3  (1.4)
Paracetamol 17 (11.3)  19  (9.0)Pediatric  prescription  according  to  the  best  evidence  
frequencies  for  which  it  has  not  been  approved,  thus  con-
ﬁguring  ‘‘off  label’’  use.  This  situation  may  contribute  to
children’s  exposure  to  adverse  events,  mainly  due  to  inade-
quate  drug  use.1
Data  on  clinical  practice  in  pediatrics  regarding  the  use  of
these  drugs,  considering  the  best  available  evidence  and  use
approved  by  regulatory  agencies  are  uncertain.  Therefore,
this  study  aimed  to  verify  the  frequency  of  prescription  of
analgesics,  antipyretics,  and  NSAIDs  according  to  the  best
scientiﬁc  evidence  and  use  approved  by  regulatory  agencies.
Methods
Study  design,  location  and  period
This  was  a  cross-sectional  study,  based  on  the  analysis  of
pediatric  prescriptions  and  information  provided  by  care-
givers.
The  authors  chose  to  perform  an  exploratory,  descriptive
study  aiming  to  identify,  record,  and  analyze  the  charac-
teristics  to  generate  a  hypothesis  about  the  criteria  used  in
pediatric  prescription  of  analgesic,  antipyretic,  and  NSAIDs.
Although  this  subject  can  be  a  constant  target  of  debate,  it
has  not  been  explored  in  depth.
The  study  was  initiated  after  approval  by  the  Ethics
and  Research  Committee,  Universidade  de  Sorocaba  (UNISO)
(Document  No.  037/08,  11/19/2008).
Selection  of  the  study  sites,  criteria  and  case
management  procedures
Data  collection  was  carried  out  in  nine  private  pharmacies
and  nine  Basic  Health  Units  (BHUs)  from  the  Brazilian  Uni-
ﬁed  Health  System  in  the  municipality  of  Sorocaba,  SP,  which
were  chosen  by  drawing  lots,  considering  their  geograph-
ical  location.  The  ﬁeld  research  was  conducted  for  nine
months.  Volunteers  (caregivers  who  had  a  pediatric  prescrip-
tion)  were  recruited  to  participate  in  the  study  according
to  order  of  arrival  at  the  pharmacy.  The  research  was  con-
ducted  once  a  week  at  different  hours.  This  study  used  two
data  sources:  pediatric  prescriptions  and  interviews  with
caregivers  who  had  the  prescriptions.  Details  on  eligibility
criteria,  data  collection,  interviews,  and  the  questionnaire
used  have  been  previously  published  by  Ferreira  et  al.11
Indication  classiﬁcation  according  to  the  best
available evidence  and  approval  of  regulatory
agencies
For  the  indication  classiﬁcation  according  to  the  best  avail-
able  clinical  evidence  of  efﬁcacy,  theoretical  data  from
Dynamed® (EBSCO,  MA,  USA),12 Clinical  Evidence,13 and
Drugdex® System  Thomson  Micromedex14 were  used.  To  ver-
ify  the  approved  indications,  drug  registration  data  from  the
Brazilian  Health  Surveillance  Agency  (Agência  Nacional  de
Vigilância  Sanitária  --  ANVISA)  and  from  the  Food  and  Drug
Administration  (FDA)  were  used.
Drug  indication  was  classiﬁed  according  to  recommen-
dation  of  use:  use  is  not  recommended  (i.e.,  it  can  be
used  with  precautions)  and  contraindicated  use  (absolutely83
revents  the  use).  Information  on  patient  characteris-
ics  (age,  comorbidity,  among  others)  and  the  diagnosis
eported  by  the  caregiver  were  veriﬁed  considering  the
ecommended  information  on  use  found  in  the  databases.
ata  analysis
ontinuous  variables  were  described  by  means  and  standard
eviations  or  median,  minimum,  and  maximum  values,
s  appropriate,  whereas  binary  variables  were  described
y  proportions.  A  descriptive  exploratory  analysis  was
mployed.
The  reported  indications  were  classiﬁed  as:  (i)  those  with
eﬁned  scientiﬁc  evidence;  (ii)  those  with  no  contraindica-
ions  for  use;  (iii)  those  approved  by  a regulatory  agency;  or
iv)  those  without  these  properties.
esults
ample  composition  is  described  in  Fig.  1.
Sample  characteristics  were  described  in  the  study  by
erreira  et  al.11 There  was  a  higher  prevalence  of  three  or
ore  drugs  per  prescription,  found  in  the  age  group  of  1--
 years  (interquartile  range,  3.5--8.7),  and  60%  of  the  pre-
criptions  failed  to  mention  the  medical  specialty.  In  51.3%
f  cases,  the  mothers  were  the  caregivers  who  took  the
rescription  to  be  ﬁlled.
The  150  patients  were  taking  506  drugs,  of  which  431
85.2%)  were  prescribed.  However,  caregivers  of  58  children
eported  that  they  were  also  using  other  medications,  of
hich  75  (14.8%)  were  not  included  in  the  analyzed  prescrip-
ion  and  were  therefore  the  result  of  other  prescriptions  or
elf-medication.  Ninety-one  patients  did  not  use  any  drugs
ther  than  those  listed  in  the  assessed  prescription  (data  not
hown).
In  the  150  prescriptions,  the  seven  analgesics,  antipyret-
cs,  and  NSAIDs  identiﬁed  were  prescribed  164  times  for
11  indications.  This  means  there  were  prescriptions  with
ore  than  one  drug  from  this  group.  The  most  com-(N02BE01)
Pyroxicam  (M01AC01)  2  (1.3)  6  (2.8)
ATC, Anatomical Therapeutic Chemical Code.
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Prescriptions of potentially eligible
pediatricv patients (n=245)
Pediatric prescriptions and interviews with
caregivers
included (n=150)
Excluded (n=95) 
Not the child's parents/tutors or did not go to the
medical consultation (n=90) 
Did not agree to participate in the study (n=5)
N-SUS
(n=49)
SUS
(n=101)
SUS,
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aFigure  1  Flowchart  of  sample  composition.  N-
ases,  (63.5%)  were  for  the  treatment  of  symptoms  of  ﬂu,
olds,  inﬂuenza-related  infections,  tonsillitis,  pharyngitis,
nd  other  respiratory  diseases  (J00-J11.9).  The  most  fre-
uent  indications  for  ibuprofen,  in  17  cases,  (32.7%)  were  to
reat  unspeciﬁed  symptoms  and  signs,  such  as  pain,  fever,
eadache,  and  others  (R50-R52).
Table  2  shows  the  non-recommended  and  contraindicated
se  of  analgesics,  antipyretics,  and  NSAIDs.  In  this  sample,
ix  (2.84%)  cases  were  indications  to  treat  symptoms  asso-
iated  with  allergic  conditions  (asthma  or  rhinitis),  which
s  not  recommended  due  to  the  possibility  of  disease  exac-
rbation.  Additionally,  nimesulide  (M01AX17)  and  piroxicam
M01AC01)  were  indicated  for  pain  and  fever  management
n  children  younger  than  12  years.
Table  3  shows  the  indications  with  no  evidence  of  bene-
t  according  to  the  best  scientiﬁc  evidence  and  the  number
f  indications  not  approved  by  ANVISA  or  the  FDA.  It  was
bserved  that  100%  of  the  reported  indications  for  acetylsal-
cylic  acid  (N02BA01,  B01A),  dipyrone  (N02BB02),  nimesulide
(
r
Table  2  Characterization  of  non-recommended  use  (use  with  cau
prescriptions,  considering  patient  characteristics  and  clinical  indic
Type  of  recommendation  Drug  Type
Non-recommended  use
(use  with  caution)  n  =  11
(5.2%)
Dipyrone  (N02BB02)  Sick
Ketoprofen  (M01AE03) Asth
Bron
Ibuprofen (M01AE01) Asth
Alle
Esop
Paracetamol  (N02BE01)  Bron
Contraindicated  use  n  =  5
(2.4%)
Pyroxicam  (M01AC01) Inﬂu
Hea
Acu
Nimesulide  (M01AX17) Tons
Fev
AA, analgesic and antipyretic; NSAIDs, non-steroidal anti-inﬂammatory
a According to Dynamed (https://dynamed.ebscohost.com), Clini
Drugdex® System. Thomson Micromedex, Greenwood Village, Colorado non-SUS;  SUS,  Brazilian  Uniﬁed  Health  System.
M01AX17),  and  piroxicam  (M01AC01)  had  no  clinical  studies
o  support  their  use.
Acetylsalicylic  acid  had  ﬁve  indications:  four  for  the
reatment  of  sickle  cell  anemia  and  one  for  tonsillitis,
hose  prescription  curiously  stated  that  a  tablet  should
e  diluted  in  half  a  glass  of  water  for  gargling  every  8  h
or  5  days.  These  instructions  are  not  approved  by  health
gencies  and  have  no  recommended  use  based  on  scientiﬁc
vidence.
In  this  sample,  dipyrone  was  prescribed  to  82  patients
54.6%)  and  was  combined  with  other  analgesics  and
ntipyretics  (AA)  or  NSAIDs  in  eight  (9.7%)  cases.  The  doses
ere  higher  than  those  recommended  by  regulatory  agen-
ies  or  even  the  drug  leaﬂets  in  41  (55.4%)  prescriptions.
any  of  them  included  a  recommended  use  that  does  not
ppear  in  any  ofﬁcial  protocol  or  consulted  database.Ibuprofen  was  prescribed  for  52  clinical  conditions;  in  19
36.5%),  its  use  is  not  based  in  scientiﬁc  evidence  or  autho-
ized  by  any  health  agency.  It  is  noteworthy  that  there  were
tion)  and  contraindicated  use  of  AA  and  NSAIDs  found  in  the
ation  (reported  diagnosis).
 of  indication  Rationalea
le  cell  anemia  (n  =  1)  Can  intensify  the  crises
ma  (n  =  1) Can  intensify  the  crises
chitis  (n  =  2)  Can  intensify  the  crises
ma  (n  =  3)  Can  intensify  the  asthma  crises
rgic  rhinitis  (n  =  2)  Can  intensify  the  bronchitis  crises
hageal  reﬂux  (n  =  1)  Can  intensify  the  bronchitis  crises
chitis  (n  =  1)  Can  intensify  the  bronchitis  crises
enza  (n  =  1)  Contraindicated  for  the  age  group
dache  (n  =  1)  Contraindicated  for  the  age  group
te  cough  (n  =  1)  Contraindicated  for  the  age  group
illitis  (n  =  1)  Contraindicated  for  the  age  group
er  (n  =  1)  Contraindicated  for  the  age  group
 drugs.
cal Evidence (http://clinicalevidence.bmj.com/x/index.html),
, USA (http://www.micromedex.com).
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Table  3  Frequency  of  reported  indications,  with  no  scientiﬁc  evidence  of  beneﬁt  and  use  not  approved  by  health  agencies.
Drug  name  ATC  Total  of
indications
Indications  with
no  evidence
n (%)
Indications  not  approved
by  health  agencies
ANVISA  FDA
n (%)  n  (%)
Acetylsalicylic  acid  N02BA01  5  (2.3)  5  (100)  5  (100)  5  (100)
Ketoprofen M01AE03  19  (9.0)  4  (21.0)  4  (21.0)  19  (100)
Dipyrone N02BB02  107  (50.7)  15  (14.0)  15  (14.0)  107  (100)
Ibuprofen M01AE01  52  (24.6)  19  (36.5)  19  (36.5)  19  (36.5)
Nimesulide M01AX17  3  (1.4)  3  (100)  3  (100)  3  (100)
Paracetamol  N02BE01  19  (9.0)  4  (21.0)  4  (21.0)  4  (21.0)
Pyroxicam M01AC01  6  (2.8)  6  (100)  6  (100)  6  (100)
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indications  for  patients  with  bronchitis,  stomatitis,  reﬂux,
rhinitis-sinusitis,  and  cough.
Paracetamol  was  indicated  for  19  clinical  conditions,  four
of  which  (21%)  without  scientiﬁc  evidence,  including  respi-
ratory  allergies,  reﬂux,  cough,  and  stomatitis.
Discussion
Main  ﬁndings
The  prescriptions  (150)  containing  the  seven  analgesic,
antipyretic,  NSAIDs  (acetylsalicylic  acid,  ketoprofen,  dipy-
rone,  ibuprofen,  nimesulide,  paracetamol,  and  piroxicam)
for  pediatric  use  had  56  (26.5%)  indications  with  no  scien-
tiﬁc  evidence.  Of  the  211  reported  indications,  14  (6.6%)
were  not  authorized  by  any  regulatory  agency,  11  (5.2%)
were  not  recommended  or  should  be  used  with  caution,  and
ﬁve  (2.4%)  had  contraindicated  use.
Among  these  seven  drugs  that  had  100%  indications  not
approved  by  the  FDA  or  ANVISA,  mainly  because  they  were
prescribed  to  children  younger  than  12  years,  are  ketopro-
fen  (approved  by  ANVISA,  but  not  by  the  FDA),  nimesulide
(approved  by  ANVISA,  but  not  by  the  FDA),  and  piroxicam
(not  approved  by  either  agency).  Dipyrone  is  not  approved
for  use  by  the  FDA.
Comparison  with  other  studies
In  the  present  study,  the  highest  prevalence  of  use  of  anal-
gesic,  antipyretic,  NSAIDs  with  no  evidence  of  beneﬁt  was
found  for  drugs  prescribed  to  children  younger  than  the  rec-
ommended  age.  Several  drugs  whose  use  was  approved  in
Brazil  in  2009  (ketoprofen,  nimesulide,  and  piroxicam)  have
use  restrictions  according  to  age,  as  speciﬁed  by  regulatory
agencies  in  other  countries.
It  is  noteworthy  the  case  of  nimesulide,  which  was
never  approved  for  pediatric  use  and  whose  sales  have
been  suspended  in  several  countries  (Ireland,  England,
Australia,  France,  Finland,  Portugal,  and  Spain)15 due  to
the  possibility  of  liver  damage,  skin  reactions,  and  fatal
Reye’s  syndrome;  it  was  initially  approved  for  pediatric  and
adult  use  in  Brazil.  The  approval  of  nimesulide  for  pediatric
use  in  Brazil  before  2007,  without  more  conclusive  studies
regarding  its  safety  in  this  population,14 was  surprising  and
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an  explain  the  inadequate  prescriptions  of  this  medication
till  observed  in  the  present  sample.  Currently,  ANVISA
equires  leaﬂets  to  include:  ‘‘This  product  is  not  suitable
or  children  younger  than  12  years.’’
However,  when  accessing  drug  sales  sites16 it  is  possible  to
dentify  in  the  Brazilian  market  at  least  16  laboratories  that
anufacture  nimesulide  as  oral  solution  at  concentrations  of
0  mg/mL,  50  mg  mL,  or  100  mg/mL,  whose  drug  leaﬂets  still
ring  dose  recommendation  for  children  aged  >1  year  old  of
 drop/kg  for  the  treatment  of  pain  and  injuries.  Conversely,
hen  the  same  query  is  carried  out  in  ANVISA  electronic
rug  information  site,  only  four  laboratories  have  registered
he  drug  leaﬂet  of  nimesulide  as  oral  solution,  where  the
ollowing  orientations  can  be  found:  ‘‘Adult  and  pediatric
se  in  children  older  than  12  years’’  and  ‘‘This  product  is
ontraindicated  for  children  younger  than  12  years.’’17
This  discrepancy  in  information  can  confound  pre-
cribers,  healthcare  professionals,  and  consumers,  increas-
ng  the  risks  of  inappropriate  use  of  this  medication  by  the
ediatric  population.
The  World  Health  Organization  has  twice  issued  warnings
gainst  the  marketing  of  nimesulide;  in  2003,  it  was  placed
n  the  category  of  special  products  under  pharmacovigi-
ance.  In  2007,  the  EMEA  started  a  systematic  analysis  of
iver  damage  caused  by  this  product  and  decided  to  main-
ain  it  in  the  market,  with  its  use  approved  for  children  older
han  12  years,  providing  they  are  under  constant  surveil-
ance  and  limiting  the  use  to  a  maximum  of  15  consecutive
ays.18
A  similar  situation  was  observed  with  piroxicam  in
razil.  Until  2009,  drug  presentations  included  oral  solu-
ion/drops  without  age-restricted  use.  Currently,  piroxicam
s  no  longer  found  in  this  pharmaceutical  form  and  presen-
ation,  and  its  indication  is  restricted  to  children  older  than
2  years.
As  for  the  ketoprofen,  it  appears  that  it  is  sold  in
razil  in  the  pediatric  formulation  as  a  medication  with
nalgesic  and  antipyretic  properties  at  low  doses,  as  well
s  anti-inﬂammatory  properties  at  larger  doses,  indicated
or  the  symptomatic  relief  of  fever  and/or  pain  in  children
lder  than  6  months.  The  leaﬂet  contains  directions  for
se  in  special  populations,  that  is,  children  younger  than
 months,  in  whom  drug  safety  and  efﬁcacy  have  not  been
stablished  yet.19 The  FDA  does  not  approve  its  use  in  the
ediatric  population,  but  considers  it  effective  in  cases
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não esteroides. Temas selecionados. 2010;5:1--15 [cited
28.03.15]. Available from http://www.cff.org.br/cebrim/6  
f  fever  (Class  IIb,  category  B),  osteoarthritis  (class  IIb,
ategory  C),  pain  (class  IIa,  category  B)  and  rheumatoid
rthritis  (class  IIb,  category  C).13
Ufer  et  al.  conﬁrmed  the  association  between  the  use
f  drugs  not  approved  for  pediatric  use  and  the  preva-
ence  of  adverse  effects.1 Wilton  et  al.  observed  that  20%  of
ediatric  prescriptions  in  Sweden  contained  drugs  recently
ntroduced  in  the  market,  including  a  percentage  of  drugs
ith  some  contraindication  for  the  age  range.20 In  this
linical--epidemiological  scenario,  it  is  believed  that  the
umber  of  medications  considered  inappropriate  for  pedi-
tric  use  is  higher  than  that  disclosed  by  several  studies.21,22
In  10%  of  the  present  sample,  two  AA  or  NSAIDs  were
ncluded  in  the  same  prescription,  to  be  used  alternately.
his  indication  lacks  evidence,  which  increases  the  risk
f  liver  damage  and  may  create  doubts  for  the  caregiver
bout  administration  intervals.23,24 A  study  in  Argentina,
ith  1600  pediatricians,  showed  that  59%  of  them  alter-
ate  two  antipyretics,  and  concluded  that  this  practice  is
ore  common  among  physicians  with  less  experience.25 It
s  odd  that  some  clinical  protocols  of  the  Brazilian  Ministry
f  Health  indicate  this  practice;  one  noteworthy  example  is
he  treatment  of  dengue  fever.
Considering  the  uncertainty  surrounding  the  superiority
r  safety  of  combined  antipyretic  regimens  when  compared
ith  monotherapy,  paracetamol  or  ibuprofen  alone  should
ontinue  to  be  used.  National  Institute  of  Health  and  Clini-
al  Excellence  (NICE)  guidelines  state  that  paracetamol  and
buprofen  should  not  be  routinely  administered  together
r  used  interchangeably.  However,  if  the  patient  does  not
espond  to  one  of  these  drugs,  an  alternative  drug  could  be
sed.26
Another  interesting  ﬁnding  in  the  present  sample  was
elated  to  the  prescribed  dose.  Dipyrone,  the  drug  with  the
ighest  prevalence  of  prescriptions  at  inadequate  doses,  had
5.4%  of  prescriptions  above  the  recommended  or  approved
oses.  These  data  are  different  from  those  obtained  by  Fer-
eira  et  al.,27 who  observed  dipyrone  use  at  lower  doses
dministered  by  routes  not  indicated  to  children  younger
han  1  year.  Alves  et  al.28 observed  that  children  received
oses  higher  than  those  recommended  by  the  drug  leaﬂet,
ncreasing  the  risks  of  adverse  events,  including  hypoten-
ion.
The  calculation  of  the  pediatric  dose  is  still  a  major  ther-
peutic  problem.  Dose  calculation  based  on  the  patient’s
ge  is  not  always  the  best  option,  especially  in  infants,  and
an  result  in  overdose.  Patients  of  the  same  age  may  differ  in
ody  mass29;  however,  calculating  the  pediatric  dose  based
n  body  weight  of  the  subject  is  not  indicated  either,  as  it
s  known  that  children’s  maturation  process  occur  gradually
nd  does  not  correspond  to  the  individual  gain  in  stature.30
tudies  with  this  age  group  are  still  necessary  to  establish
he  optimal  dose.  This  fact  may  explain  the  observed  dose
ariations  in  this  sample.
tudy  strengths  and  limitationshis  study  presented  the  ﬁrst  detailed  data  on  use  of  anal-
esic,  antipyretic,  and  NSAIDs  in  pediatric  patients  in  Brazil.
atients  were  included  shortly  after  the  medical  consul-
ation,  which  reduced  the  confounding  factor  of  recallingFerreira  TR,  Lopes  LC
he  reported  indications  or  the  child’s  signs  and  symptoms.
atients  were  identiﬁed  throughout  the  year,  in  all  four
easons,  reducing  possible  seasonality  biases.  Additionally,
oncerned  about  the  population  representativeness,  the
uthors  selected  18  different  locations,  including  patients
reated  at  the  public  and  the  private  sectors.
A  detailed  interview  script  was  used  by  two  trained  inter-
iewers,  and  the  answers  were  cross-checked  with  the  data
ontained  in  the  prescriptions.  Perhaps  the  main  limitation
f  this  study  was  its  sample  size,  but  regarding  this  aspect,
 descriptive  exploratory  analysis  was  chosen,  with  no  asso-
iations  between  variables.
Sources  of  evidence  recommended  by  regulatory  agen-
ies  and  by  the  World  Health  Organization  were  used  for
ata  analysis  (Dynamed,  Clinical  Evidence,  Drugdex® System
homson  Micromedex).12--14
ractical  implications  and  ﬁnal  considerations
rug  prescription  should  be  based  on  the  best  available  evi-
ence  of  beneﬁt  and  on  the  values  and  preferences  of  the
ndividual  that  will  be  treated.
Addressing  the  parents’  anxiety  and  fears  about  fever  and
ducating  them  on  the  immunological  usefulness  of  fever
nd  the  risks  associated  with  the  overuse  of  antipyretics
hould  remain  a  priority.
There  is  urgent  need  for  intervention  measures  in  drug
ispensing,  which  will  result  in  the  rational  use  of  these
rugs,  as  well  as  a  positive  impact  on  health  outcomes.
rug  registration  policies  that  consider  the  best  available
cientiﬁc  evidence  could  decrease  the  advent  of  drugs  with
nclear  use  indications.
These  ﬁndings  show  that  important  differences  can
e  observed  between  clinical  practice  in  pediatrics
egarding  the  use  of  AA  and  NSAIDs  and  recommenda-
ions  based  on  the  best  available  scientiﬁc  evidence  and  use
pproved  by  regulatory  agencies.
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